Dr. Melania Tesio – Oncologia –  Best Researcher Award

Posted on by sciencefather

Dr. Melania Tesio - Oncologia -  Best Researcher Award

INSERM - France

Author Profile 

SCOPUS 

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications 

  • Title: Tell me who you go with and I'll tell you who you are
    Author: M. Tesio
    Journal: HemaSphere, 2024, 8(1), e36
  • Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
    Author: M. Tesio
    Journal: Frontiers in Oncology, 2024, 14, 1372133
  • Title: Sunscreen to Protect the Marrow
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(9), pp. E941
  • Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(2), pp. E827
  • Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(1), pp. E816

Prof. Jerzy trojan – Immuno – gene therapy – Excellence in Innovation

Posted on by sciencefather

Prof. Jerzy trojan - Immuno - gene therapy - Excellence in Innovation

CEDEA/ICGT and INSERM/Univ. Paris-Saclay - France

Author Profile

ORCID

Early academic pursuits 🎓

Jerzy trojan completed his doctorate d’état ès sciences (hdr) at the prestigious sorbonne - p&m curie. during this formative period, he laid the groundwork for his future contributions to biomedical science, specifically in the field of cancerology. his early research endeavors, characterized by a rigorous scientific approach, focused on critical aspects of oncology and laid the foundation for his later groundbreaking work.

Professional endeavors 🏥

Jerzy has held various esteemed positions throughout his career, reflecting his commitment to advancing cancer research. he is currently a visiting professor at the insitm, cancer center, and paris-saclay university in villejuif, france, where he has been since 2019. before this, he served as president and research director at the international cancer gene therapy and oncology diagnostics center (ceadea) in bogota, colombia, and has also held prominent roles in institutions across the usa and europe, including case western reserve university and the sidney kimmel cancer center. these diverse experiences have equipped him with a comprehensive understanding of both the scientific and clinical aspects of cancer treatment.

Contributions and research focus 🔬

Dr. trojan is best known for establishing cancer gene therapy, particularly immuno-gene therapy, as a pivotal domain within oncology. his pioneering research, highlighted in publications from 1993, led to significant advancements in the treatment of glioblastoma, showcasing the therapeutic potential of gene therapy. Immuno - gene therapy additionally, he explored the intersection between neuro-ontogenesis and neuro-oncogenesis, identifying afp and igf-i as novel biomarkers, which have implications for understanding central nervous system differentiation and cancer progression.

Accolades and recognition 🏆

In recognition of his substantial contributions to biomedical science, jerzy was elected as a member of the prestigious french academy of medicine (anm) in paris in 2017. his extensive body of work includes nearly 370 publications, encompassing 140 articles, 102 book chapters, and four books, which have garnered over 3,500 Immuno - gene therapy citations. this impressive scholarly output underscores his impact and influence in the field of cancer research.

Impact and influence 🌍

Dr. trojan's research has significantly shaped the landscape of cancer therapy, particularly in immunotherapy. his establishment of immuno-gene therapy has opened new avenues for treating aggressive cancers, thus influencing both academic research and clinical practices. his work has not only contributed to theoretical Immuno - gene therapy advancements but has also informed practical applications that benefit patients facing challenging diagnoses.

Legacy and future contributions đź”®

With an enduring commitment to advancing cancer research, jerzy trojan continues to influence the field through his current role as a visiting professor and research director. his legacy is evident in the ongoing projects aimed at improving cancer treatment outcomes, particularly through innovative therapeutic strategies. as he continues to publish and mentor the next generation of researchers, his contributions will undoubtedly have a lasting impact on the future of oncology and gene therapy.

Notable Publications 

  • Title: Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment
    Author: J. Trojan et al.
    Journal: Medical Research and Its Applications, Vol. 6, Pages 114-127
    DOI: 10.9734/bpi/mria/v6/7520C
    Publication Date: June 3, 2024
  • Title: Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
    Author: J. Trojan
    Journal: Current Medicinal Chemistry, Vol. 31, Pages 1982-2002
    DOI: 10.2174/0109298673231106095141
    Publication Date: March 11, 2024
  • Title: Establishment of Cancer Gene Therapy
    Author: J. Trojan
    Journal: Cambridge Scholars Publishing
    Publication Date: March 2, 2023
  • Title: Neoplastic brain, glioblastoma and immunotherapy
    Author: J. Trojan et al.
    Journal: In: Brain and Spinal Tumors - Primary and Secondary, Ed. L.R. Morgan, F.B. Sarica, InTechOpen
    Publication Date: 2020
  • Title: In vitro technical aspects of Anti–Gene IGF-I vaccines against glioma
    Author: J. Trojan et al.
    Journal: IBR, Vol. 3(1), Pages 43-48
    Publication Date: 2019

Dr. Vikas Shukla – Nanomedicine and Immunology – Best Researcher Award

Posted on by sciencefather

Dr. Vikas Shukla - Nanomedicine and Immunology - Best Researcher Award

AIIMS, New Delhi - India 

Author Profile

GOOGLE SCHOLAR 

Early academic pursuits đź“š

Vikas Shukla's academic journey began with a deep-rooted passion for nanobiotechnology and immunology. He dedicated himself to gaining a solid foundation in the life sciences, eventually leading him to pursue advanced studies in these cutting-edge fields. His education, characterized by rigorous training, provided the tools necessary for his future contributions to scientific research. Over the years, vikas built an impressive knowledge base in bacterial culture, cell culture, and immunoassays, which would serve as the backbone of his research career.

Professional endeavors 🏢

currently serving as a research scientist-II at the all india institute of medical sciences (aiims) in new delhi, india, vikas brings over 8 years of extensive experience to the forefront. His role at aiims, within the department of plastic, reconstructive & burns surgery, involves not only laboratory-based research but also project management. This balance between hands-on science and overseeing project timelines ensures that he contributes effectively to the scientific and clinical goals of his department.

Contributions and research focus 🔬

Vikas's research primarily revolves around nanobiotechnology and immunology, with a keen focus on innovative solutions in medical science. He has demonstrated exceptional expertise in bacterial culture, cell culture, immunoassays, and small animal handling. His work seeks to bridge the gap between complex scientific Nanomedicine and Immunology theories and their real-world applications, particularly in healthcare. Vikas’s research outputs have helped advance understanding in both fundamental immunological responses and the application of nanotechnology in therapeutic treatments.

Accolades and recognition 🏅

throughout his career, vikas has received commendations for his meticulous work and contributions to the field. His ability to keep projects both on time and on Nanomedicine and Immunology budget while maintaining high scientific standards has not gone unnoticed. He is widely recognized among his peers and colleagues for his diligence, precision, and ability to translate complex scientific concepts into more accessible knowledge. His exceptional communication skills have further bolstered his reputation as a skilled researcher and project manager.

Impact and influence 🌍

Vikas’s research holds significant implications for the fields of immunology and nanobiotechnology, particularly within clinical settings. His work on developing innovative medical treatments and enhancing immunological responses has the potential to save lives and improve patient outcomes. His influence extends beyond the laboratory, as his project management skills ensure that critical research is completed efficiently, benefiting both the scientific community and society as a whole.

Legacy and future contributions đź”®

looking ahead, Vikas Shukla’s legacy will likely be defined by his contributions to advancing the use of nanotechnology in medicine. His ongoing work at aiims and within the broader scientific community will continue to impact the development of new therapeutic approaches and enhance our understanding of immune Nanomedicine and Immunology responses. His commitment to pushing the boundaries of science while managing complex projects ensures that his influence will be felt for years to come.

Notable Publications 

Smart Drug-Delivery Systems in the Treatment of Rheumatoid Arthritis: Current, Future Perspectives  2021

Dynamic light scattering (DLS) particle size analysis for biomedical nanotechnology  2023

Downmodulation of lysophosphatidic acid by Berberine loaded folate-conjugated glycol chitosan nanoparticles  2022

Therapeutic use of mesenchymal stem cells against SARS-Cov-2: present and future prospects  2022

Phytomedicine Meets Nanotechnology: A Cellular Approach to Rheumatoid Arthritis Treatment 2024